Background and objectives: Although genetic linkage analyses and association studies have implicated several loci and candidate genes in predisposition to chronic kidney disease (CKD), the genes that underlie genetic susceptibility to this condition have remained uncharacterized. The purpose of the present study was to identify genetic variants that confer susceptibility to CKD in Japanese individuals.
T he Japanese population has a large proportion of elderly individuals, whose number will continue to increase for at least the next two decades. The incidence of renal disease, especially that of chronic kidney disease (CKD) and end-stage renal disease (ESRD), will increase as the size of the elderly population increases, given that renal function decreases with age (1) . CKD is a global public health problem; individuals with CKD are at increased risk not only for ESRD but also for a poor cardiovascular outcome and premature death (2, 3) . Disease prevention is an important strategy for reducing the overall burden of CKD and ESRD, and the identification of markers for disease risk is key both for risk prediction and for potential intervention to reduce the chance of future cardiovascular events (4) .
Although genetic linkage analyses (5, 6) and association studies (7-9) have implicated several loci and candidate genes in predisposition to CKD, the genes that contribute to genetic susceptibility to this condition remain to be identified definitively. In addition, given the ethnic differences in lifestyle and environmental factors as well as in genetic background, it is important to examine genetic polymorphisms related to CKD in each ethnic group. We have now performed an association study for 40 polymorphisms of 32 candidate genes and CKD in 5217 Japanese individuals. The purpose of the present study was to identify genetic variants that confer susceptibility to CKD and thereby to provide a basis for the personalized prevention of this condition.
Materials and Methods

Study Population
The study population comprised 5217 unrelated Japanese individuals (2955 men, 2262 women) who either visited outpatient clinics of, or were admitted to, one of the participating hospitals (Gifu Prefectural General Medical Center and Gifu Prefectural Tajimi Hospital in Gifu Prefecture, Japan; and Hirosaki University Hospital, Reimeikyo Rehabilitation Hospital, and Hirosaki Stroke Center in Aomori Prefecture, Japan) between October 2002 and March 2008 because of various symptoms or for an annual health checkup, or who were recruited to a population-based prospective cohort study of aging and age-related diseases in Gunma Prefecture and Tokyo, Japan.
GFR was estimated with the use of the simplified prediction equation derived from the modified version of that described in the Modification of Diet in Renal Disease (MDRD) Study as proposed by the Japanese Society of Nephrology (10) , suggestive of a poor outcome for such individuals (12) . We thus adopted the criterion of an eGFR of Ͻ50 ml min Ϫ1 1.73 m Ϫ2 for diagnosis of CKD in the present study. On the basis of this criterion, 778 subjects (480 men, 298 women) were diagnosed with CKD. The control subjects comprised 4439 individuals (2475 men, 1964 women) whose eGFR was Ն60 ml min Ϫ1 1.73 m
Ϫ2
. The control subjects were recruited from community-dwelling healthy individuals or the patients who visited outpatient clinics regularly for treatment of various common diseases. Although some of these subjects had hypertension, diabetes mellitus, or dyslipidemia, none of them had systemic conditions such as neoplasia, pulmonary disease, or infectious disease. Subjects with CKD and controls thus either had or did not have conventional risk factors for CKD, including hypertension (systolic BP of Ն140 mmHg or diastolic BP of Ն90 mmHg, or both, or taking antihypertensive medication), diabetes mellitus (fasting blood glucose of Ն6.93 mmol/L or hemoglobin A 1c of Ն6.5%, or both, or taking antidiabetes medication), or hypercholesterolemia (serum total cholesterol of Ն5.72 mmol/L or taking lipid-lowering medication). Current smokers were defined as those who smoked a total of Ն100 cigarettes or for more than six months and smoked daily recently for one month; former smokers as those who smoked a total of Ն100 or for more than six months but did not smoke recently for one month; and nonsmokers as those who did not smoke a total of Ն100 cigarettes or for more than six months or did not smoke recently for one month. Former smokers were classified into smokers. The diagnosis of myocardial infarction was confirmed by the presence of a wall motion abnormality by left ventriculography and identification of the responsible stenosis in any of the major coronary arteries or in the left main trunk by coronary anigiography. The diagnosis of ischemic stroke was based on the occurrence of a new and abrupt focal neurologic deficit, with neurologic symptoms and signs persisting for Ͼ24 h; it was confirmed by positive findings in computed tomography or magnetic resonance imaging (or both) of the head.
The 
Selection of Polymorphisms
Our aim was to identify genes associated with CKD in the Japanese population in a case-control association study by examining the relations of one to three polymorphisms of each candidate gene to this condition. With the use of public databases, including PubMed (NCBI) and Online Mendelian Inheritance in Man (OMIM), we selected 32 candidate genes that have been characterized and suggested to be associated with CKD. On the basis of published studies or by searching PubMed and single nucleotide polymorphism (SNP) databases [dbSNP (NCBI) and Japanese SNP database (JSNP)], we further selected 40 polymorphisms of these genes, most located in the promoter region or exons, that might be expected to result in changes in the function or expression of the encoded protein (Supplementary Table 1 ). Wild-type and variant alleles of the polymorphisms were determined from the original sources.
Genotyping of Polymorphisms
Venous blood (7 ml) was collected into tubes containing 50 mmol/L ethylenediaminetetraacetic acid (disodium salt), and genomic DNA was isolated with a kit (Genomix; Talent, Trieste, Italy). Genotypes of the 40 polymorphisms were determined at G&G Science (Fukushima, Japan) by a method that combines the PCR (PCR) and sequence-specific oligonucleotide probes with suspension array technology (Luminex, Austin, TX). Primers, probes, and other PCR conditions for genotyping polymorphisms found to be significantly [false discovery rate (FDR) Ͻ 0.05] associated with CKD by the chi-square test are shown in Supplementary Table 2 . Detailed genotyping methodology was described previously (13) .
Statistical Analysis
Quantitative data were compared between subjects with CKD and controls by the unpaired t test. Categorical data were compared by the chi-square test. Allele frequencies were estimated by the gene counting method, and the chi-square test was used to identify departures from Hardy-Weinberg equilibrium. In the initial screen, the genotype distributions (3 ϫ 2) or allele frequencies (2 ϫ 2) of each polymorphism were compared between subjects with CKD and controls by the chi-square test. Given the multiple comparisons of genotypes with CKD, the FDR (14) was calculated from the distribution of P values for allele frequency of the 40 polymorphisms. Polymorphisms with an FDR of Ͻ0.05 were further examined by multivariable logistic regression analysis with adjustment for covariates. Multivariable logistic regression analysis was thus performed with CKD as a dependent variable and independent variables including age, sex (0 ϭ woman, 1 ϭ man), body mass index (BMI), smoking status (0 ϭ nonsmoker, 1 ϭ smoker), history of hypertension, diabetes mellitus, or hypercholesterolemia (0 ϭ no history, 1 ϭ positive history), and genotype of each polymorphism; the P value, FDR, odds ratio, and 95% confidence interval (CI) were calculated. Each genotype was assessed according to dominant (0 ϭ wildtype homozygote, 1 ϭ heterozygote ϩ variant homozygote), recessive (0 ϭ wild-type homozygote ϩ heterozygote, 1 ϭ variant homozygote), and additive [(0,0) ϭ wild-type homozygote (1,0), ϭ heterozygote, (0,1) ϭ variant homozygote] genetic models. Additive models included the additive 1 model (heterozygotes versus wild-type homozygotes) and the additive 2 model (variant homozygotes versus wild-type homozygotes), which were analyzed simultaneously with a single statistical model. In multivariable logistic regression analysis, the FDR was calculated from the distribution of 30 P values for dominant, recessive, and additive genetic models of selected polymorphisms. Odds ratio of current or former smokers versus nonsmokers were also calculated. Allele frequencies of the eight identified polymorphisms were compared by the chi-square test between subgroups of 772 subjects with CKD and 772 controls matched for age, sex, smoking status, and the prevalence of hypertension, diabetes mellitus, and hypercholesterolemia individually. With the exception of the initial screen by the chi-square test and multivariable logistic regression analysis (FDR Ͻ0.05), a P value of Ͻ0.05 was considered statistically significant. Statistical significance was examined by two-sided tests performed with JMP version 6.0 and JMP Genomics version 3.2 software (SAS Institute, Cary, NC).
Results
The characteristics of the 5217 study subjects are shown in Table 1 . Age, the frequency of male subjects, systolic BP, fasting plasma glucose level, blood glycosylated hemoglobin content, the serum concentration of triglycerides, as well as the prevalence of hypertension, diabetes mellitus, myocardial infarction, and ischemic stroke, were greater, whereas the percentage of smokers and the serum concentration of HDL-cholesterol were lower in subjects with CKD than in controls.
Comparison of allele frequencies with the chi-square test revealed that the Ϫ219G3 T polymorphism of APOE (rs405509), the Ϫ519A3 G polymorphism of MMP1 (rs1144393), the Ϫ413T3 A polymorphism of HMOX1 (rs2071746), the Ϫ866G3 A polymorphism of UCP2 (rs659366), the Ϫ1607/1G32G polymorphism of MMP1 (rs1799750), the 1429C3 T polymorphism of GNB3 (rs5446), the A3 G (Lys45Glu) polymorphism of MMP3 (rs679620), the G3 A (Ala163Thr) polymorphism of AGTR1 (rs12721226), the G3 A (Gly670Arg) polymorphism of PE-CAM1 (rs1131012), and the Ϫ55C3 T polymorphism of UCP3 (rs1800849) were significantly associated with the prevalence of CKD as defined by an FDR of Ͻ0.05 (Table 2 ). The genotype distributions for these 10 polymorphisms as well as for an additional seven polymorphisms that were related to CKD as defined by a P value of Ͻ0.05 for allele frequency are also shown in Table 2 . In control subjects, the genotype distributions for eight of the initial ten polymorphisms (not those for HMOX1 and GNB3) were in Hardy-Weinberg equilibrium (Supplementary Table 3) ; the polymorphisms of HMOX1 and GNB3 were therefore excluded from subsequent analysis.
Multivariable logistic regression analysis with adjustment for age, sex, BMI, smoking status, and the prevalence of hypertension, diabetes mellitus, and hypercholesterolemia revealed that the Ϫ219G3 T polymorphism of APOE (dominant, recessive, and additive 2 models), the Ϫ519A3 G polymorphism of MMP1 (dominant and additive 1 and 2 models), the Ϫ866G3 A polymorphism of UCP2 (additive 2 model), the Ϫ1607/1G32G polymorphism of MMP1 (recessive model), the A3 G (Lys45Glu) polymorphism of MMP3 (dominant and additive 1 and 2 models), the G3 A (Ala163Thr) polymorphism of AGTR1 (dominant and additive 1 models), the G3 A (Gly670Arg) poly- Table 4 ). Comparison of allele frequencies of the eight identified polymorphisms by the chi-square test between subgroups of CKD and control subjects matched for age, sex, smoking status, and the prevalence of hypertension, diabetes mellitus, and hypercholesterolemia individually revealed that the Ϫ519A3 G polymorphism of MMP1 and the Ϫ866G3 A polymorphism of UCP2 were significantly (P Ͻ 0.05) associated with CKD (Table 4) . Comparison of allele frequencies of the eight identified polymorphisms by the chisquare test between subjects with or without diabetes mellitus (Supplementary Table 5 ) or between subjects with or without hypertension ( Supplementary Table 6 ) revealed that none of these polymorphisms were related to diabetes mellitus or hypertension.
Discussion
We examined the possible relations of 40 polymorphisms in 32 candidate genes to the prevalence of CKD in 5217 Japanese individuals. Our association study with three steps of analysis (chi-square test, multivariable logistic regression analysis, and matched case-control analysis) revealed that the Ϫ519A3 G polymorphism of MMP1 (rs1144393) and the Ϫ866G3 A polymorphism of UCP2 (rs659366) were significantly associated with the prevalence of CKD.
The Ϫ519A3 G polymorphism of MMP1, which is located in the promoter region of the gene, has been related to the risk of myocardial infarction as part of a haplotype including other polymorphisms of MMP1 (15) . In addition, the G allele of this polymorphism was associated with an increased intima-media thickness of the carotid artery in a German population with hypertension (16) . We have now shown that the Ϫ519A3 G polymorphism of MMP1 was significantly associated with the prevalence of CKD, with the G allele representing a risk factor for this condition. Effects of this polymorphism on the development of atherosclerosis may account for its association with CKD.
The A allele of the Ϫ866G3 A polymorphism in the promoter region of UCP2 was associated with increased transcription of the gene in a human adipocyte cell line PAZ-6 and with a modest but significant reduction in the prevalence of obesity (17) . The A allele of the Ϫ866G3 A variant was also associated with reduced risk of coronary heart disease in men with type 2 diabetes mellitus in a 6-yr prospective study (18) . The deletion allele of the insertion/deletion polymorphism in the 3Ј region of UCP2 was related to ESRD in Indian subjects (19) . We have now shown that the Ϫ866G3 A polymorphism of UCP2 was significantly associated with the prevalence of CKD, with the A allele representing a risk factor for this condition, although the underlying molecular mechanism remains elucidated. There were differences in the results between multivariable logistic regression analysis and chi-square test individually matched for covariates. Multivariable logistic regression analysis could not fully overcome substantial differences between the CKD and control groups, while the number of control individuals was smaller in the matched case-control analysis than in multivariable logistic regression analysis. Given that the Ϫ519A3 G polymorphism of MMP1 and the Ϫ866G3 A polymorphism of UCP2 were significantly associated with CKD in both analyses, these genes may be considered as susceptibility loci for this condition.
Although previous studies showed that smoking is a risk factor for CKD (20) and that current smokers are at higher risk of CKD compared with former smokers (21) , the frequency of smoking was significantly lower in subjects with CKD than in controls in the present study, even though there was a possibility of more cigarettes and the longer term of smoking in subjects with CKD than in controls. In a case-control study, it is important that controls are selected from the group of individuals who would have been considered for selection as cases, if they had the disease. Furthermore, the exposure history of controls should be representative of the exposure history of the population from which the cases were selected. Given that subjects were recruited by different methods, selection bias could not be excluded in the present study.
Our study has several limitations: (1) We used an estimated GFR (eGFR) instead of a directly measured rate to define CKD. (2) We were not able to obtain information on proteinuria, the underlying renal disease, or the primary cause of CKD in all subjects with CKD. Such information could be obtained by detailed clinical examination, including renal biopsy, but such diagnostic procedures are not considered feasible for a study whose subjects are recruited from the general population. (3) It is possible that one or more of the polymorphisms associated with CKD in the present study are in linkage disequilibrium with other polymorphisms in the same gene or in other nearby genes that are actually responsible for the development of this condition. (4) The functional relevance of the identified polymorphisms to gene transcription or to protein structure or function was not determined in the present study. (5) Given that the subjects with CKD in the present study were survivors of CKD, they were likely not representative of all CKD patients, and there was a possibility of survivor bias. (6) Although we adopted the criterion of FDR Ͻ0.05 for association to compensate for the multiple comparisons of genotypes with CKD, it is not possible to exclude completely potential statistical errors such as false positives. The association of gene polymorphisms with CKD in the present study was not confirmed in the databases of other studies. Our present study can thus be considered as hypothesis generating.
In conclusion, our present results suggested that MMP1 and UCP2 might be susceptibility loci for CKD in the Japanese population. Determination of genotypes for the studied polymorphisms of these genes may prove informative for prediction of the genetic risk for CKD. Validation of our findings will require their replication with independent subject panels as well as long-term follow-up to examine the association of the identified genetic variants with the rate of decline in eGFR. 
